GLP-1 Dose Escalation: How and Why Your Dose Goes Up
Every GLP-1 medication starts at a dose too low to work, on purpose. Here is the week-by-week escalation schedule for Ozempic, Wegovy, Mounjaro and Zepbound, why the steps are spaced four weeks apart, and what usually happens in the days after each increase.
If you have just started a GLP-1 medication, the first dose you are given is deliberately too low to produce much effect. That is not a mistake or a cautious doctor being slow. It is how these medications are designed to be introduced, and understanding the logic makes the first few months considerably easier to get through.
This guide sets out the standard escalation schedules from the manufacturers’ prescribing information, explains why the steps sit four weeks apart, and describes what most people experience in the days after each increase. For background on how these medications work in the first place, see our complete guide to GLP-1 injections.
Why GLP-1 Doses Start Low
GLP-1 receptor agonists slow the rate at which the stomach empties. That is central to how they reduce appetite, and it is also the source of most early side effects. Introduce the full dose immediately and the digestive system has no chance to adapt — nausea and vomiting become severe enough that many people stop treatment altogether.
Clinical trials consistently show that stepping the dose up gradually preserves the full effect on blood sugar and weight while substantially improving tolerability. The starting dose is therefore best understood as a preparation phase rather than treatment:
- It gives gastric emptying time to slow gradually instead of abruptly.
- It lets you and your clinician see how you respond before committing to a higher dose.
- It keeps side effects at a level most people can work through rather than one that ends treatment.
Standard Dose Escalation Schedules
The tables below reproduce the escalation schedules published in each medication’s prescribing information. Your own plan may differ — clinicians routinely adjust the pace for individual patients — but these are the reference schedules those adjustments start from.
Ozempic (semaglutide, type 2 diabetes)
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 0.25 mg weekly | Initiation only — not intended for blood sugar control |
| 5–8 | 0.5 mg weekly | First therapeutic dose |
| 9–12 | 1 mg weekly | Optional increase if further control is needed |
| 13+ | 2 mg weekly | Maximum recommended dose |
Wegovy (semaglutide, weight management)
Wegovy contains the same active ingredient as Ozempic but escalates to a higher maximum, with one additional step:
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 0.25 mg weekly | Initiation |
| 5–8 | 0.5 mg weekly | Second step |
| 9–12 | 1 mg weekly | Third step |
| 13–16 | 1.7 mg weekly | Fourth step |
| 17+ | 2.4 mg weekly | Maintenance dose |
Mounjaro and Zepbound (tirzepatide)
Tirzepatide acts on two receptors rather than one and follows a simpler rule: increase by 2.5 mg after at least four weeks at the current dose, up to a maximum of 15 mg.
| Weeks | Dose | Purpose |
|---|---|---|
| 1–4 | 2.5 mg weekly | Initiation only — not intended for blood sugar control |
| 5–8 | 5 mg weekly | First maintenance dose |
| 9–12 | 7.5 mg weekly | Optional increase |
| 13–16 | 10 mg weekly | Optional increase |
| 17–20 | 12.5 mg weekly | Optional increase |
| 21+ | 15 mg weekly | Maximum recommended dose |
What Happens After Each Increase
Most people find that a step up brings back symptoms they thought they had left behind. This is normal and follows a fairly predictable shape:
- Days 1–3: appetite drops noticeably again, and nausea often returns — usually milder and shorter-lived than at the very first dose, because your body has already adapted once.
- Days 4–7: symptoms typically ease as the higher level stabilises.
- Weeks 2–4: most people settle into the new dose, and this is when the added benefit of the increase becomes visible.
If the pattern at a new dose looks nothing like this — symptoms intensifying rather than easing after the first week, or an inability to keep fluids down — that is a reason to contact your clinician rather than wait it out. Our guide to GLP-1 side effects and how to manage them covers the warning signs in more detail.
When a Dose Increase Is Delayed or Held
Staying at your current dose beyond four weeks is common and is not a setback. Clinicians frequently extend an interval or hold a dose when:
- Side effects from the previous step have not settled yet.
- Your blood sugar or weight response is already where it needs to be at the current dose.
- You are unwell, travelling, or otherwise unable to eat and drink normally.
- You have missed doses and the level in your body is no longer where the schedule assumes.
The maximum dose is a ceiling, not a target. Many people reach a satisfactory result at an intermediate dose and stay there indefinitely.
How to Prepare for Your Next Step Up
A little planning around the increase makes the first week markedly easier:
- Schedule the increase for a quieter stretch — avoid the day before travel, a big presentation or a long drive.
- Reduce portion sizes for the first few days and eat more slowly than feels necessary.
- Keep fat and heavily spiced food light in that first week; both sit in a slowed stomach longer.
- Drink steadily through the day rather than large amounts at once.
- Protect protein intake — appetite drops fastest right after a step up, and protein is what usually gets squeezed out.
- Write down what you experience, with dates. At your next appointment this is far more useful than trying to remember.
Why Tracking Your Escalation Matters
Dose escalation is the period where a written record earns its keep. Four weeks is long enough that memory blurs, and the question your clinician will ask — how bad were the side effects at each dose, and how long did they last — is nearly impossible to answer accurately from recall. A log turns that into a straightforward conversation.
Dailivity records your dose history and injection dates, reminds you when the next dose is due, tracks side effects with severity over time, and exports the whole picture as a PDF you can bring to your appointment. Download Dailivity free on the App Store to keep your escalation in one place.
Frequently Asked Questions
How long does it take to reach the full GLP-1 dose?
On the standard schedule, Ozempic reaches its 2 mg maximum at around week 13 and Wegovy reaches 2.4 mg at week 17. Tirzepatide reaches 15 mg at about week 21. In practice many people take longer because a step gets delayed, and plenty stop at an intermediate dose that already works well for them.
Can I increase my dose sooner than four weeks?
No. The four-week interval exists because that is roughly how long the body needs to adapt to the current level, and shortening it markedly increases the risk of severe gastrointestinal side effects. Only your prescriber can change the interval, and they generally lengthen it rather than shorten it.
Do side effects get worse at every increase?
Symptoms commonly return briefly after each step, but they are usually milder and shorter than at the first dose because your body has already adapted once. If each increase is worse than the last, tell your clinician — that pattern is not typical.
What if I miss a dose during escalation?
Missed dose rules differ by medication and by how much time has passed, so follow the instructions for your specific product or ask your pharmacist. If you have missed several doses in a row, do not simply resume at your previous dose — the level in your body has fallen and your clinician may want to restart lower.
Is a higher dose always more effective?
Higher doses produce greater average effects in trials, but averages are not individuals. Some people reach their goal at 0.5 mg or 5 mg and gain little from going further except more side effects. The right dose is the lowest one that achieves your treatment goal.
Can I go back down to a lower dose?
Yes, and it is a routine clinical decision rather than a failure. If side effects at a new dose are not settling, clinicians frequently step back to the previous dose, allow more time, and try again later.
Sources
- Ozempic (semaglutide) prescribing information — Novo Nordisk / U.S. FDA
- Wegovy (semaglutide) prescribing information — Novo Nordisk / U.S. FDA
- Mounjaro (tirzepatide) prescribing information — Eli Lilly / U.S. FDA
- Zepbound (tirzepatide) prescribing information — Eli Lilly / U.S. FDA
Written by the Dailivity health content team.
This content is for educational purposes only and does not constitute medical advice. Always consult your clinician for personal treatment decisions.